Indication: For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
Pharmacology: Ceftriaxone is a cephalosporin/cephamycin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. Ceftriaxone has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ceftriaxone results from the inhibition of cell wall synthesis and is mediated through Ceftriaxone binding to penicillin binding proteins (PBPs). Ceftriaxone is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.
Mechanism Of Action: Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death.
Drug Category: Anti-bacterial Agents; Cephalosporins; ATC:J01DD04
Interactions:
DrugBank: Interactions for Ceftriaxone
Interactions for Ceftriaxone:
No information provided.
Chemical IUPAC Name: 8-[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl]amino-4-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid
Chemical Formula: C18H18N8O7S3
Half Life: 5.8-8.7 hours
Drug Type: Approved Drug
# Accession No: APRD00395
CAS Registry Number: 73384-59-5
Ceftriaxone News (When available)
Analysts` corner: Hero HondaDec 27, 2005 Business Standard, The FDC of ceftriaxone fortified by sulbactam has become an Rs 70 crore brand since seven months of launch and is expected to become a Rs 500 crore brand over ...
Real growth will happen from 2007: OrchidDec 10, 2005 Sify, ...| Read more Finance news. |. Three of its Cephalosporin-based formulations are selling in the US markets - Cefazolin, Cephalexin and Ceftriaxone. ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
